Table 1. Clinical features of patients with typical CD10-negative and CD10+ MCL.
| CD10-negative MCL (n = 212) | CD10+ MCL (n = 30) | P Value | |
|---|---|---|---|
| Medium Age (yrs, range) | 67 (29–95) | 68 (49–84) | 0.89 |
| Age > 60 (yrs)* | 77 (163/212) | 70 (21/30) | 0.49 |
| Male:Female | 5.1:1 (177/35) | 1.3:1 (17/13) | 0.002 |
| Nodal Presentation* | 50 (107/212) | 63 (19/30) | 0.33 |
| BM Positive* | 74 (145/196) | 64 (16/25) | 0.34 |
| CNS Positive* | 70 (7/10) | 56 (5/9) | 0.65 |
| Elevated WBC* | 17 (29/171) | 24 (5/21) | 0.54 |
| Elevated Serum LDH* | 26 (43/168) | 45 (9/20) | 0.11 |
| Stage III or IV* | 76 (144/190) | 95 (19/20) | 0.05 |
| High MIPI* | 23 (31/135) | 44 (7/16) | 0.12 |
| Initial Chemotherapy* | 0.47 | ||
| Hyper-CVAD+/−R | 55 (106/194) | 54 (14/26) | |
| CHOP+/−R | 20 (38/194) | 27 (7/26) | |
| Other | 15 (29/194) | 19 (5/26) | |
| Initial CR* | 83 (132/159) | 69 (18/26) | 0.11 |
| With SCT* | 16 (34/195) | 15 (4/26) | 1.0 |
* = %(positive/evaluated); BM, bone marrow; CNS, central nervous system; WBC, white blood cells; LDH, lactate dehydrogenase; MIPI, Mantle cell lymphoma International Prognostic Index; Hyper-CVAD, hyperfractionated cyclophophsmide, vincristine, doxorubicin, dexamethasone, cytarabine and methotrexate; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, rituximab; CR, complete response; SCT, stem cell transplant.